---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-082089"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2025-04-16T23:59:59+00:00"
generated_at: "2026-05-23T13:31:56.098912+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Phathom Pharmaceuticals appoints Theodore R. Schroeder to board, effective April 16, 2025

## Summary
- Schroeder appointed as Class I director, term expiring at 2026 annual meeting; will serve on audit committee.
- Received option for 35,000 shares and 21,000 RSUs, both vesting over three years; plus cash compensation.
- Former CEO of Nabriva Therapeutics, co-founded Cadence Pharmaceuticals (bought by Mallinckrodt), held senior roles at Elan, Dura, and Bristol-Myers Squibb.
- Board determined Schroeder meets Nasdaq independence standards; no related party transactions.

## SEC filing metadata
- accession: 0001193125-25-082089
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2025-04-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312525082089/0001193125-25-082089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312525082089/d943974d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-082089
- JSON: https://secwatch.observer/filing/0001193125-25-082089.json
- Plain text: https://secwatch.observer/filing/0001193125-25-082089.txt

## Key facts
- Executive change
  Theodore R. Schroeder was appointed as Director at Phathom Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: The board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Theodore R. Schroeder to the Board as a Class I director, effective April 16, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312525082089/0001193125-25-082089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.